---
title: "VK2735 in Chronic weight management: Metabolic and bariatric surgery"
description: "Formulary evidence on VK2735 in Chronic weight management: Metabolic and bariatric surgery. Topics: ASMBS and IFSO indications for metabolic and bariatric surgery, ADA recommendations for metabolic surgery in type 2 diabetes, Perioperative mortality and complications, Long-term survival after metabolic-bariatric surgery, and 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/metabolic-and-bariatric-surgery"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Metabolic and bariatric surgery

<a id="heading-2.2.2.1.6"></a>

## 2.2.2.1.6 Metabolic and Bariatric Surgery

<a id="topic-2.2.2.1.6-1"></a>

### ASMBS and IFSO indications for metabolic and bariatric surgery

> “Metabolic and bariatric surgery (MBS) is recommended for individuals with a body mass index (BMI) >35 kg/m2, regardless of presence, absence, or severity of co-morbidities.”
> “MBS should be considered for individuals with metabolic disease and BMI of 30-34.9 kg/m2.”
> “BMI thresholds should be adjusted in the Asian population such that a BMI > 25 kg/m2 suggests clinical obesity, and individuals with BMI > 27.5 kg/m2 should be offered MBS.”
> “Long-term results of MBS consistently demonstrate safety and efficacy.”

Source: [Eisenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9834364/)

<a id="topic-2.2.2.1.6-2"></a>

### ADA recommendations for metabolic surgery in type 2 diabetes

> “Consider metabolic surgery as a weight and glycemic management approach in people with type 2 diabetes with BMI ≥30.0 kg/m2 (or ≥27.5 kg/m2 in Asian American individuals) who are otherwise good surgical candidates.”
> “People who undergo metabolic surgery should receive long-term medical and behavioral support and routine micronutrient, nutritional, and metabolic status monitoring.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

<a id="topic-2.2.2.1.6-3"></a>

### Perioperative mortality and complications

> “Perioperative mortality rates are typically 0.1–0.5%, similar to those for common abdominal procedures such as cholecystectomy and hysterectomy (149,150). Major complications occur in 2–6% of those undergoing metabolic surgery, which compares favorably with the rates for other commonly performed elective operations (150).”
> “Minor complications and need for operative reintervention occur in up to 15% (149,151–153).”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

<a id="topic-2.2.2.1.6-4"></a>

### Long-term survival after metabolic-bariatric surgery

> “In the overall population consisting 174 772 participants, metabolic-bariatric surgery was associated with a reduction in hazard rate of death of 49·2% (95% CI 46·3-51·9, p<0·0001) and median life expectancy was 6·1 years (95% CI 5·2-6·9) longer than usual care.”

Source: [Syn et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33965067/)

<a id="topic-2.2.2.1.6-5"></a>

### Long-term follow-up after surgery

> “Multiple studies have demonstrated that long-term follow up with the surgical team reduces drastically to 30 % in two years and less than 10 % in 10 years”

Source: [Pennings et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11997402/)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
